Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc. (FRTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
frtx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Fresh Tracks Therapeutics, Inc.You FRTX | $6M | N/A | — | -$0.96 |
 Aptose Biosciences Inc. APTO | $4M | N/A | — | $0.00 |
 BiondVax Pharmaceuticals Ltd. BVXV | $5M | N/A | — | -$0.20 |
 Entero Therapeutics, Inc. ENTO | $14M | N/A | — | -$4.05 |
 Nabriva Therapeutics plc NBRVF | $0M | N/A | — | -$21.32 |
 Neuphoria Therapeutics Inc. NEUP | $25M | N/A | — | -$0.23 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Fresh Tracks Therapeutics, Inc. (FRTX) measures how much investors pay for each dollar of the company's trailing earnings. FRTX's current PE ratio of N/A is calculated by dividing its stock price of $0.94 by its TTM earnings per share of -$0.96.
Frequently asked questions
FRTX pe ratio · 6 questionsFRTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.94 and TTM EPS of -$0.96. Data sourced from Financial Modeling Prep via FRTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Fresh Tracks Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09